The cost item is a major one. As I said in my presentation, just on pharmaceuticals, we're now spending at total of $27.7 billion and they are now the second largest component of our total health spending. That amount has gone up quite dramatically over the last 25 years. Cost is certainly going to be a major concern for governments looking at a national pharmacare program. Pushing up the costs further, which I think the TPP will do, is going to make it even more difficult to afford a national pharmacare program.
On February 4th, 2014. See this statement in context.